Chronisch thromboembolische pulmonale Hypertonie (CTEPH) 2014 (Langversion)

Zusammenfassung

Dieses Positionspapier fasst die wichtigen Entwicklungen im Bereich der Diagnostik und Therapie der chronisch thromboembolischen pulmonalen Hypertonie (CTEPH) zusammen. Basierend auf den Empfehlungen der Task Force für CTEPH beim 5. Weltsymposium für Pulmonale Hypertonie (PH) in Nizza 2013 bezieht es Stellung zu offenen Fragen, die bei der Behandlung von Patienten mit CTEPH entstehen. Die Arbeitsgruppe wurde im Rahmen des jährlich stattfindenden DACH-Symposiums zur PH in Heidelberg 2013 berufen.

Bei Verdacht auf CTEPH sollten eine Echokardiographie und eine Spiroergometrie erfolgen. Bei positivem Befund ist die bildgebende Methode der Wahl die Ventilations-Perfusionsszintigraphie. Entscheidungen über die Therapie von Patienten mit CTEPH sollten in einem Expertenzentrum auf der Basis einer interdisziplinären Diskussion mit einem erfahrenen PEA-Chirurgen getroffen werden. Die pulmonale Endarteriektomie (PEA) ist Therapie der Wahl für Patienten mit CTEPH. Der Einsatz einer PH-spezifischen medikamentösen Therapie setzt eine umfangreiche Diagnostik entsprechend den Empfehlungen der Leitlinien voraus, sollte in PH-erfahrenen Zentren initiiert werden und sollte nur erfolgen, wenn ausgeschlossen wurde, dass ein Patient durch die potenziell kurative PEA behandelt werden kann.

Abstract

This position paper summarises current developments in chronic thromboembolic pulmonary hypertension (CTEPH) including diagnostic approaches and treatment options. Based on the guidelines of the task force of CTEPH experts at the 5th World Symposium on Pulmonary Hypertension in Nice 2013. Open questions arising during the treatment of patients with CTEPH are addressed. Patients with suspected CTEPH should undergo echocardiography and cardiopulmonary exercise testing. A ventilation/perfusion scan is the recommended imaging test for screening in the diagnostic algorithm for the evaluation of CTEPH. CTEPH-patients should be discussed in an expert center with an interdisciplinary team and an experienced PEA surgeon to decide the further treatment. Pulmonary endarterectomy (PEA) is the treatment of choice for patients with CTEPH. Medical therapy with PH-targeted medications for inoperable CTEPH and residual disease after PEA should only be initiated if evaluation reveals that the patient is no candidate for a PEA. Current data suggest that CTEPH patients treated with PEA have a better long-term survival rate and quality of life than patients treated with medical therapy

Schlüsselwörter

chronische thromboembolische pulmonale Hypertonie - Diagnose - Lungenembolie - Therapie

Keywords

chronic thromboembolic pulmonary hypertension - diagnosis - pulmonary embolism - treatment

• Literatur

• 1 Kim NH, Delcroix M, Jenkins DP et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: D92-9
• 2 Simonneau G, Delcroix M, Lang I et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results of an international prospective registry comparing operated versus non-operated patients. Am J Respir Crit Care Med 2013; 187: A5365
• 3 Lang IM, Simonneau G, Pepke-Zaba JW et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost 2013; 110: 83-91
• 4 Pepke-Zaba J, Delcroix M, Lang I et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124: 1973-81
• 5 Bonderman D, Turecek PL, Jakowitsch J et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003; 90: 372-6
• 6 Bonderman D, Jakowitsch J, Adlbrecht C et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93: 512-6
• 7 Yao W, Firth AL, Sacks RS et al. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009; 296: L870-8
• 8 Bonderman D, Wilkens H, Wakounig S et al. Risk factors for chronic thromboembolic pulmonary hypertension. The European respiratory journal 2009; 33: 325-31
• 9 Lang IM, Pesavento R, Bonderman D et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. The European respiratory journal 2013; 41: 462-8
• 10 Natali D, Jais X, Abraham M et al. Chronic Thromboembolic Pulmonary Hypertension Associated With Indwelling Port-A-Cath® Central Venous Access Systems. Am J Respir Crit Care Med 2011; 183: A2409
• 11 Supple GE, Ren JF, Zado ES et al. Mobile thrombus on device leads in patients undergoing ablation: identification, incidence, location, and association with increased pulmonary artery systolic pressure. Circulation 2011; 124: 772-8
• 12 Kim NH. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 584-8
• 13 Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685-92
• 14 Lang IM, Marsh JJ, Olman MA et al. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-21
• 15 Held M, Grün M, Holl R et al. Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. Respiration 2014; 379-87
• 16 Held M, Grün M, Holl R et al. Chronisch thrombembolische pulmonale Hypertonie: Latenz bis zur Diagnosesicherung und klinischer Zustand bei Diagnosestellung. Deutsch med Wochenschr 2014; 139: im Druck
• 17 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-60
• 18 Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-64
• 19 Mayer E, Jenkins D, Lindner J et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141: 702-10
• 20 Tscholl D, Langer F, Wendler O et al. Pulmonary thromboendarterectomy – risk factors for early survival and hemodynamic improvement. Eur J Cardiothorac Surg 2001; 19: 771-6
• 21 Azarian R, Wartski M, Collignon MA et al. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med 1997; 38: 980-3
• 22 Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-72
• 23 Grünig E, Barner A, Bell M et al. Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154 (Suppl. 01) S3-12
• 24 Rudski LG, Lai WW, Afilalo J et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713; quiz 86-8
• 25 Fisher MR, Forfia PR, Chamera E et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-21
• 26 Fisher MR, Criner GJ, Fishman AP et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. The European respiratory journal 2007; 30: 914-21
• 27 Scheidl SJ, Englisch C, Kovacs G et al. Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. The European respiratory journal 2012; 39: 119-24
• 28 Jaff MR, McMurtry MS, Archer SL et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-830
• 29 Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154 Suppl 1: S54-60
• 30 Tunariu N, Gibbs SJ, Win Z et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48: 680-4
• 31 McLaughlin VV, Langer A, Tan M et al. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest 2013; 143: 324-32
• 32 Bajc M, Neilly JB, Miniati M et al. EANM guidelines for ventilation/perfusion scintigraphy: Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging 2009; 36: 1356-70
• 33 Bajc M, Neilly JB, Miniati M et al. EANM guidelines for ventilation/perfusion scintigraphy: Part 2. Algorithms and clinical considerations for diagnosis of pulmonary emboli with V/P(SPECT) and MDCT. Eur J Nucl Med Mol Imaging 2009; 36: 1528-38
• 34 Sugimura K, Fukumoto Y, Miura Y et al. Three-dimensional-optical coherence tomography imaging of chronic thromboembolic pulmonary hypertension. Eur Heart J 2013; 34: 2121
• 35 Ley S, Ley-Zaporozhan J, Pitton MB et al. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2012; 22: 607-16
• 36 Wijesuriya S, Chandratreya L, Medford AR. Chronic pulmonary emboli and radiologic mimics on CT pulmonary angiography: a diagnostic challenge. Chest 2013; 143: 1460-71
• 37 Hoey ET, Mirsadraee S, Pepke-Zaba J et al. Dual-energy CT angiography for assessment of regional pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension: initial experience. AJR Am J Roentgenol 2011; 196: 524-32
• 38 Sugiyama M, Fukuda T, Sanda Y et al. Organized thrombus in pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension; imaging with cone beam computed tomography. Jpn J Radiol 2014; epub ahead of print April 24
• 39 Hoeper MM, Mayer E, Simonneau G et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011-20
• 40 Jamieson SW, Kapelanski DP, Sakakibara N et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: 1457-62; discussion 62-4
• 41 Madani MM, Auger WR, Pretorius V et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg 2012; 94: 97-103; discussion
• 42 Thistlethwaite PA, Kaneko K, Madani MM et al. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg 2008; 14: 274-82
• 43 Macchiarini P, Kamiya H, Hagl C et al. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: is deep hypothermia required?. Eur J Cardiothorac Surg 2006; 30: 237-41; discussion 41-3
• 44 Jamieson S. Editorial Comment. Eur J Cardiothorac Surg 2006; 30: 241-3
• 45 Kunihara T, Tscholl D, Langer F et al. Cognitive brain function after hypothermic circulatory arrest assessed by cognitive P300 evoked potentials. Eur J Cardiothor Surg 2007; 32: 507-13
• 46 Vuylsteke A, Sharples L, Charman G et al. Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet 2011; 378: 1379-87
• 47 Bonderman D, Skoro-Sajer N, Jakowitsch J et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115: 2153-8
• 48 Kramm T, Eberle B, Guth S et al. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005; 28: 882-8
• 49 Berman M, Tsui S, Vuylsteke A et al. Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy. Ann Thorac Surg 2008; 86: 1261-7
• 50 Ogino H, Ando M, Matsuda H et al. Japanese single-center experience of surgery for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2006; 82: 630-6
• 51 Jenkins DP, Madani M, Mayer E et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. The European respiratory journal 2013; 41: 735-42
• 52 Archibald CJ, Auger WR, Fedullo PF et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999; 160: 523-8
• 53 Feinstein JA, Goldhaber SZ, Lock JE et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 2001; 103: 10-3
• 54 Kataoka M, Inami T, Hayashida K et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5: 756-62
• 55 Mizoguchi H, Ogawa A, Munemasa M et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5: 748-55
• 56 Inami T, Kataoka M, Shimura N et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv 2013; 6: 725-36
• 57 Andreassen AK, Ragnarsson A, Gude E et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 2013; 99: 1415-20
• 58 Hoeper MM. Chronic thromboembolic pulmonary hypertension at the crossroad. The European respiratory journal 2014; 43: 1230-2
• 59 Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537
• 60 Ghofrani HA, Distler O, Gerhardt F et al. [Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010]. Dtsch Med Wochenschr 2010; 135 (Suppl. 03) S87-101
• 61 Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336: 393-8
• 62 Olsson KM, Delcroix M, Ghofrani HA et al. Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129: 57-65
• 63 Jensen K, Kerr K, Fedullo P et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary endarterectomy. Circulation 2009; 120: 1248-54
• 64 Jais X, D'Armini AM, Jansa P et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 2127-34
• 65 Ghofrani HA, D'Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-29
• 66 Nagaya N, Shimizu Y, Satoh T et al. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 2002; 87: 340-5
• 67 Ono F, Nagaya N, Okumura H et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003; 123: 1583-8
• 68 Krug S, Hammerschmidt S, Pankau H et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008; 76: 154-9
• 69 Nagaya N, Sasaki N, Ando M et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123: 338-43
• 70 Scelsi L, Ghio S, Campana C et al. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. Ital Heart J 2004; 5: 618-23
• 71 Skoro-Sajer N, Bonderman D, Wiesbauer F et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007; 5: 483-9
• 72 Ghofrani HA, Schermuly RT, Rose F et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-41
• 73 Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Resp J 2007; 30: 922-7
• 74 Seyfarth HJ, Hammerschmidt S, Pankau H et al. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 2007; 74: 287-92
• 75 Hoeper MM, Kramm T, Wilkens H et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005; 128: 2363-7
• 76 Badesch DB, Feldman J, Keogh A et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012; 30: 93-9
• 77 Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Resp J 2010; 36: 792-799